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Cisplatin is widely used for the treatment of various solid tumours.
However, the response to this drug varies not only between tumour
types, but also among tumours of a certain type. It is generally
believed that the anti-tumour effect of cisplatin is due to direct
binding of the drug to DNA, resulting in platinum–DNA
monoadducts and various bifunctional adducts (Fichtinger-
Schepman et al, 1985; Eastman, 1986). The main adduct formed is
cis-platinum diammine-d(GpG) (abbreviated platinum-GG), with
platinum bound to two adjacent guanines. Another major
intrastrand crosslink is cis-platinum diammine-d(ApG) (platinum-
AG), in which platinum is bound to guanine and an adjacent
adenine. The other bifunctional adducts are cis-platinum
diammine-(dG)2 (G-platinum-G), the intrastrand adducts in which
platinum is bound to two guanines separated by one or more other
nucleotide(s), and the interstrand crosslinks between two guanines
in opposite strands. These adducts can inhibit cell proliferation
and, if not repaired or tolerated, finally lead to cell death.
In patients with the same type of tumour, a fairly large inter-
individual variation in DNA adduct levels, measured in white
blood cells (WBCs), has been observed (Fichtinger-Schepman et
al, 1990; Parker et al, 1993; Poirier et al, 1993; Reed et al, 1988,
1993; Schellens et al, 1996). These clinical investigations
provided evidence that higher adduct levels correlate with a better
clinical outcome. In contrast to these findings, there are also
reports showing no correlation between adduct levels in WBCs
and the efficacy of therapy (Gupta-Burt et al, 1993; Motzer et al,
1994; Fisch et al, 1996). All these clinical studies, however, were
performed in patients with a variety of solid tumours and after
different treatment regimens, which could be a reason for the
inconsistency of the results. Furthermore, blood samples were
collected at different time points, although in most studies this
was done at 24 h after cisplatin administration. In addition, the
methods used for adduct detection and statistical analysis [using
either the highest (peak) level or the mean value over several
courses] were different between the various studies.
The basic question in all these investigations, however, is
whether or not platinum-DNA adduct levels in the tumours corre-
late with the response to the cisplatin treatment. Because it is not
feasible to obtain tumour biopsies from patients for such studies,
the readily obtainable WBCs were used in most investigations as a
substitute for the target tissue. In the present study, both the total
platinum content and the platinum–GG and platinum–AG adduct
levels were determined in human head and neck squamous cell
carcinomas (HNSCC) grown in nude mice and as cultured cells, at
various time points after the start of cisplatin treatment. Responses
of the tumours to this treatment were correlated with both total
platinum contents and these platinum–DNA adduct levels.
Because the pharmacokinetics of cisplatin are similar in nude mice
and humans (Kubota et al, 1993), this study will provide more
insight into factors involved in the clinical response of patients to
cisplatin.
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Summary Total platinum contents and cisplatin–DNA adduct levels were determined in vivo in xenografted tumour tissues in mice and in vitro
in cultured tumour cells of head and neck squamous cell carcinoma (HNSCC), and correlated with sensitivity to cisplatin. In vivo, a panel of five
HNSCC tumour lines growing as xenografts in nude mice was used. In vitro, the panel consisted of five HNSCC cell lines, of which four had
an in vivo equivalent. Sensitivity to cisplatin varied three- to sevenfold among cell lines and tumours respectively. However, the ranking of the
sensitivities of the tumour lines (in vivo), also after reinjection of the cultured tumour cells, did not coincide with that of the corresponding cell
lines, which showed that cell culture systems are not representative for the in vivo situation. Both in vitro and in vivo, however, significant
correlations were found between total platinum levels, measured by atomic absorption spectrophotometry (AAS), and tumour response to
cisplatin therapy at all time points tested. The levels of the two major cisplatin–DNA adduct types were determined by a recently developed
and improved 32P post-labelling assay at various time points after cisplatin treatment. Evidence is presented that the platinum–AG adduct, in
which platinum is bound to guanine and an adjacent adenine, may be the cytotoxic lesion because a significant correlation was found between
the platinum–AG levels and the sensitivities in our panel of HNSCC, in vitro as well as in vivo. This correlation with the platinum–AG levels was
established at 1 h (in vitro) and 3 h (in vivo) after the start of the cisplatin treatment, which emphasizes the importance of early sampling.
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Tumour lines
Human head and neck squamous cell carcinomas (HNSCC) were
used in two model systems.
In vitro
Cell lines UM-SCC-14C (abbreviated as 14C), UM-SCC-22B
(22B) and UM-SCC-35 (35) were established directly from the
tumour biopsy of the patient (Carey et al, 1990). VU-SCC-OE (OE)
and VU-SCC-RO (RO) were established from xenografts that were
initiated originally by transplanting tumour fragments from patients
into mice (Welters et al, 1997a). Cells were cultured routinely in
Dulbecco’s modified Eagle medium [Life Technologies (Gibco
BRL), Breda, The Netherlands] supplemented with 5% heat-inacti-
vated fetal calf serum (Flow, Irvine, UK), 50 U ml–1 penicillin and
50 mg ml–1 streptomycin (Life Technologies).
In vivo
Xenografts were established on female, athymic, nude-nu mice
(6–8 weeks old; Harlan, Zeist, The Netherlands) either by subcuta-
neous injection of cultured tumour cells (14C and 22B) in suspen-
sion at both sides or by implantation of tissue fragments of the
tumour from the patient (OE, RO and HN). Upon growth, the
tumour lines were maintained by serial transplantation (Braakhuis
et al, 1995). Tumour volumes (mm3) were determined twice
weekly by use of a vernier calliper and calculated according to the
formula: 0.5 ´ length ´ width ´ height. This method of measuring
tumour volumes has proved to be most accurate (Tomayko and
Reynolds, 1989). Animal experiments were performed according
to the Dutch law on animal experiments and after approval of the
appropriate ethics committees at our institutes.
DNA index
Cultured HNSCC cells were trypsinized and harvested. Tumour
tissues were dissociated by use of trypsin for 30 min at 37°C,
followed by filtration through 100-mm nylon filters in order to
obtain single cells. The DNA of these cells was labelled with the
fluorescent DNA intercalator propidium iodide as described earlier
(Welters et al, 1997a) and the DNA index was determined by flow
cytometry.
Sensitivity to cisplatin
Tumour cells in culture and tumour-bearing mice were treated with
cisplatin (Platinol, Bristol-Myers Squibb, Weesp, The
Netherlands) to determine the growth response and to obtain
samples for the analysis of total platinum and platinum–DNA
adduct levels.
In vitro
The cisplatin-induced inhibition of cell proliferation, as a measure
of the sensitivity to this drug, has been determined and published
previously (Welters et al, 1997a). The HNSCC cells were exposed
to various concentrations of cisplatin for 72 h at 37°C and the inhi-
bition of cell growth was determined colorimetrically with the
sulphorhodamin B assay (SRB). The cisplatin sensitivity was
expressed as IC50 value, i.e. the concentration of the drug causing
50% growth inhibition compared with untreated control cells.
In vivo
Mice bearing HNSCC tumours with a volume between 50 and
200 mm3 were randomly divided into treatment and control
groups, with 6–10 tumours per group. Cisplatin (7 mg kg–1) was
given intravenously, twice with a 7-day interval. The drug was
administered at the maximum tolerated dose, i.e. the dose leading
to a weight loss of no more than 5–15%. Anti-tumour activity was
expressed as growth delay factor (GDF), defined as the difference
between the mean values of the time required by tumours of
treated and control animals to double their volume, divided by the
mean value of the tumour doubling time in control mice. A second
method to quantify the therapeutic results of the cisplatin treatment
was by determination of the treated/control value (T/C), i.e. the
mean tumour volumes after treatment divided by the tumour
volumes at the start of the treatment. The lowest value of this ratio
at any time point during the observation period was considered as
optimal T/C value. Complete responses were scored when a
tumour regressed and did not show regrowth for a period of 3
months.
Intracellular cisplatin
The levels of total platinum were determined both in cultured cells
and in xenografts of cisplatin-treated mice.
In vitro
Cells were treated continuously for 1, 6, 24, 48 or 72 h with 10 mM
cisplatin, whereafter the cells were washed and harvested. Portions
of the samples were processed to determine the cellular platinum
content by atomic absorption spectroscopy (AAS) (Spectra AA-
300 Zeeman AAS, Varian, Houten, The Netherlands), as described
previously (Welters et al, 1997a).
In vivo
Tumour-bearing mice were treated twice with cisplatin as
indicated above and sacrificed at various time intervals after the
second injection (3 h, 24 h, and 3, 7 and 14 days). The tumours
were removed, quickly frozen in liquid nitrogen and stored at
–80°C. One half of each tumour was prepared for measurement of
total platinum levels by AAS according to the method of Siddik et
al (1987). The tumour halves were weighed, lysed by addition
of 0.5 ml of 1 M hyamine (benzethonium hydroxide, Sigma,
St. Louis, MO, USA), and incubated overnight at 55°C. Platinum
was measured after addition of 4.25 ml 0.2 M hydrochloric acid.
Calibration standards and quality control samples of muscle tissue
were spiked with cisplatin and treated in the same way as the
samples (Korst et al, 1998).
Platinum–DNA adducts
Portions of the cisplatin-treated cells and of the tumours obtained
from treated mice were used for the analysis of the two DNA
adducts platinum–GG and platinum–AG. Cell pellets and tumour
tissues were lysed and DNA was isolated as described by
Fichtinger-Schepman et al (1987, 1995a) and stored at –20°C until
further analysis. After enzymatic digestion of the DNA, the adduct
levels were determined by a novel, recently improved 32P post-
labelling assay after deplatination of the purified adducts (Welters
et al, 1997b). The 32P-labelled products were separated by
thin-layer chromatography and the radioactivity determined by
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phosphorimaging. The amounts of the two major intrastrand DNA
adducts platinum–GG and platinum–AG were calculated on the
basis of the labelling of a known amount of TpT, which was
included as an internal standard.
Statistical analysis
Correlations between the platinum content and DNA adduct levels
with sensitivity to cisplatin were analysed by linear regression
analysis. Only correlations with P-values of 0.05 or lower were
considered to be significant. For the analysis, the area under the
curve (AUC) was also utilized. AUC values (derived from plots of
platinum content vs time or platinum–DNA adduct levels vs time)
were calculated with the trapezoidal rule.
RESULTS
In this study, the sensitivity to cisplatin in a panel of HNSCC
xenografts (in vivo) was compared with that of the corresponding
cultured cells (in vitro) and correlated with cisplatin accumulation
and DNA adduct formation. As can be seen in Table 1, the cells
growing as xenograft or in culture are comparable with respect to
their DNA indices, with the exception of cell line RO. After
several passages of RO, large cells containing more than one
nucleus were observed, owing to the inability of the cells to
complete their cell division. It was probably for this reason that
RO cells could only be kept in culture for about 12 passages.
Consequently, sufficient amounts of these cells to determine the
cellular platinum and the platinum–DNA adduct levels could not
be obtained. Unfortunately, we were not successful in establishing
a cell line from the HN xenograft and no xenografts could be
established from the UM-SCC-35 cell line. The DNA content of
both the tumours and the cell lines was found to be rather consis-
tent over time and during various passages.
Sensitivity to cisplatin
The response of the tumours in the xenografted mice after cisplatin
treatment are given in Table 2, as well as data on the tumour
doubling times in the treated group and untreated controls. The
14C and HN xenografts were not sensitive. The best response,
even some complete responses, were observed with RO. The
intrinsic sensitivities to cisplatin of the cultured HNSCC cells were
reported previously (Welters et al, 1997a). They are included in
Table 2 to allow comparison with the in vivo data. IC50 values
ranged between 0.9 and 2.7 mM cisplatin.
Comparison of the ranking of the cisplatin sensitivities of the
xenografts with those of the corresponding cultured cells revealed
that both RO and OE differed in sensitivity when xenografted or
cultured. These two tumour lines were established directly from the
tumour biopsies obtained from the patient and the cell cultures were
derived subsequently from the xenografts. In contrast, the 14C and
22B tumour lines were established after injection of the cultured
cells into mice. To determine whether the difference between in
vitro and in vivo responses of the HNSCC lines was due to the
difference in the way the tumour lines were established, the
cultured RO and OE cells were reinjected subcutaneously into mice
and, after growth to tumours, the mice were treated with cisplatin.
The responses to cisplatin of these newly established tumours were
comparable to those of the original xenografts (data not shown).
Intracellular cisplatin
As described previously for an in vitro study on a panel of seven
HNSCC cell lines, most of which were also used in the present
work, the cellular platinum levels correlated significantly with the
IC50 values, after incubation of the cells with 10 mM cisplatin
during 1, 6, 24 or 48 h (Welters et al, 1997a). For these seven cell
lines, positive correlations were found between sensitivity and the
AUC values of the platinum vs time curves calculated from 1 h up
to each time point studied during the total cisplatin incubation
period of 48 h. The r-values were 0.83 (P = 0.017) when AUC was
calculated over 6 h, 0.78 (P = 0.031) when calculated over 24 h
and 0.78 (P = 0.032) over the 48-h time period. These correlations
were found when data for cell line OE, derived from a patient
previously treated with radiotherapy, were omitted (Welters et al,
1997a). In Figure 1, the cellular platinum levels as a function of
the exposure time are given only for those cell lines for which the
DNA adduct levels were also determined (see below).
To investigate whether the previously found correlations in vitro
also exists in vivo, platinum levels were determined in the tumours
at various time points after the second cisplatin treatment of the
Table 1 DNA index of HNSCC xenografts and the corresponding cultured
cells
Tumour Degree of DNA indexb
line differentiationa
Xenograft Cell line
14C Poorly 3.5 ± 0.1 3.1 ± 0.2
22B Moderately 2.3 ± 0.1 2.2 ± 0.5
35 NAc NA 3.0 ± 0.1
OE Moderately 3.3 ± 0.5 3.5 ± 0.3
RO Well 1.8 ± 0.2 3.7 ± 0.2
HN Poorly/moderately 3.1 ± 0.4 NA
aThe xenografts were scored pathologically as described by Van Dongen et
al (1989); bDNA index was determined by flow cytometry of the tumour cells
derived from xenografts or from cell cultures. The DNA content appeared to
be stable during several passages. The results are means ± s.d. of at least
six independent measurements; cNA, not available.
Table 2 Responses to cisplatin treatment in HNSCC xenografts and in
cultured cells
Tumour IC50 Tumour doubling Tumour responseb
line valuea time (days)b
Control Treated GDF T/C (%)
14C 2.7 ± 0.7 9.7 ± 1.6 11.6 ± 4.5 0.3 (–) 69 (–)
22B 1.2 ± 0.3 10.2 ± 2.1 21.3 ± 6.0 1.1 (+) 34 (+)
35 0.9 ± 0.8 NA NA NA NA
OE 2.3 ± 0.9 6.7 ± 1.8 12.9 ± 1.5 1.0 (+) 34 (+)
RO 2.4 ± 0.8 7.7 ± 2.0 22.8 ± 11.7 2.0 (++) 19 (++)
HN NAc 6.1 ± 2.4 11.3 ± 5.4 0.9 (–) 56 (–)
aIC50 value (in mM), the concentration of the drug causing 50% of growth
inhibition, determined in a colorimetric (SRB) assay after exposure of the
cells to cisplatin for 72 h (data from Welters et al, 1997a); bmice bearing
human head and neck tumours were treated i.v. with 7 mg cisplatin kg–1 twice
with a 7-day interval. Responses to cisplatin therapy were determined in at
least four independent experiments and expressed as GDF and T/C.
GDF < 1 or T/C > 50 corresponds to a minimal effect (–); 1 < GDF < 2 or
25 < T/C < 50 to a moderate effect (+) and GDF > 2 or T/C < 25 to a strong
effect with even some complete responses (++); cNA, not available.Pharmacodynamics of cisplatin in head and neck cancer 85
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tumour-bearing mice. As shown in Figure 2, 14C contained the
lowest and RO the highest platinum levels. Comparison of the plat-
inum levels with tumour response (expressed either as GDF or T/C;
see Table 2) revealed no significant correlations at any time point
measured. However, the AUC values of the platinum vs time curve,
determined over the whole period of 14 days tested, showed a posi-
tive correlation with the GDF (r = 0.95, P = 0.008). When the
period between 3 h and 3 days was taken as time interval for the
AUC calculation, this correlation was even more significant (r =
0.98, P = 0.0007). Similarly, this AUC significantly correlated with
the T/C values, showing an r-value of 0.86 (P = 0.045) when the
AUC was calculated over 14 days and of 0.89 (P = 0.028) when
calculated over the 3-day time period. Apparently, the amount of
platinum present during the first time period after administration of
cisplatin is very important for the efficacy of the treatment.
Platinum–DNA adducts
The kinetics of cisplatin–DNA adduct formation and removal
were studied in the cultured HNSCC cells as well as in the
xenografts. The levels of the major adducts (platinum–GG and
platinum–AG) were determined by 32P post-labelling of digested
DNA samples after deplatination of the adducts (Welters et al,
1997b). The in vitro results are depicted in Figure 1 and show that
in three of the four HNSCC cell lines the adduct levels increased
with time during the continuous exposure to cisplatin. No signifi-
cant correlation could be found between the IC50 values and either
the adduct levels at the various time points or the AUC of plat-
inum–DNA adduct levels calculated for the various time periods.
The only exception, however, was the correlation with the plat-
inum–AG adduct levels at 1 h after the start of cisplatin exposure
(r = –0.92, P = 0.045).
In vivo, the platinum–GG and platinum–AG adduct levels were
determined in portions of the same tumours that were used to
obtain the total platinum content (Figure 2). It was found that the
highest levels were reached at 3–24 h after the second injection
with cisplatin, whereafter they decreased with time. The AUC
calculated between 3 h and 14 days showed no correlation with the
tumour response to cisplatin (expressed as GDF or T/C value).
However, when the AUC was restricted to the period between 3 h
and 3 days for both adducts, a relationship could be established.
For platinum-GG, the correlation with GDF was not significant (r
= 0.82, P = 0.067), but it was for the platinum–AG adduct levels (r
= 0.86, P = 0.042). However, such a correlation was not found
when adduct data were plotted against the T/C values. When the
tumour responses were compared with the two adduct levels at the
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Figure 1 Cultured human HNSCC cells 14C (A), 22B (B), 35 (C) and OE (D) were treated continuously with 10 mM cisplatin for the time period indicated. Total
platinum content (pmol per 106 cells; left y-axis) was measured by AAS (l; solid line). The two major intrastrand platinum–DNA adducts (number of adducts per
106 nucleotides; right y-axis) were measured by the 32P post-labelling assay (Welters et al, 1997b); platinum–GG (n n; dashed line) and platinum–AG (s; dashed
line). Results are given of two independent experiments as means ± range of values86 MJP Welters et al
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various time points, a significant correlation was found only
between GDF and the platinum–AG adducts at 3 h after cisplatin
therapy (r = 0.88, P = 0.034). The platinum–AG data at 24 h did
not correlate (r = 0.86, P = 0.096). The results suggest that sensi-
tivity to cisplatin in HNSCC is determined by the amount of plat-
inum–AG adduct that is present in the cell during a short time
interval after cisplatin treatment.
DISCUSSION
The relationship of responses to cisplatin treatment with total plat-
inum content and cisplatin–DNA adduct levels was investigated in
a panel of human HNSCC cultured cells and xenografts. A different
ranking was observed when the responses of HNSCC to cisplatin
were determined in vitro or in vivo, in particular with lines OE and
15
5
0
0 100 200 300 400
5
10
15
Time (h)
P
l
a
t
i
n
u
m
 
c
o
n
t
e
n
t
P
l
a
t
i
n
u
m
–
D
N
A
 
a
d
d
u
c
t
s
0
A
10
15
5
0
0 100 200 300 400
5
10
15
Time (h)
P
l
a
t
i
n
u
m
 
c
o
n
t
e
n
t
P
l
a
t
i
n
u
m
–
D
N
A
 
a
d
d
u
c
t
s
0
B
10
15
5
0
0 100 200 300 400
5
10
15
Time (h)
P
l
a
t
i
n
u
m
 
c
o
n
t
e
n
t
P
l
a
t
i
n
u
m
–
D
N
A
 
a
d
d
u
c
t
s
0
C
10
15
5
0
0 100 200 300 400
25
50
Time (h)
P
l
a
t
i
n
u
m
 
c
o
n
t
e
n
t
P
l
a
t
i
n
u
m
–
D
N
A
 
a
d
d
u
c
t
s
0
D
10
15
5
0
0 100 200 300 400
5
10
15
Time (h)
P
l
a
t
i
n
u
m
 
c
o
n
t
e
n
t
P
l
a
t
i
n
u
m
–
D
N
A
 
a
d
d
u
c
t
s
0
E
10
Figure 2 Mice bearing the human HNSCC tumour 14C (A), 22B (B), OE (C), RO (D) or HN (E) were treated i.v. with 7 mg cisplatin kg–1, twice with a 7-day
interval. Tumours were removed at various time points after the second administration of the drug (3 h, 24 h, and 3, 7 and 14 days). Total platinum levels (fmol
platinum mg–1 tissue; left y-axis) in these tumours were determined by AAS (l; solid line) and the platinum–DNA adducts (number of adducts per 106
nucleotides; right y-axis) were measured by the 32P post-labelling assay (Welters et al, 1997b); platinum–GG (n n; dashed line) and platinum–AG (s; dashed
line). Results are given of three independent experiments as means ± s.d.Pharmacodynamics of cisplatin in head and neck cancer 87
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RO. These discrepancies could not be ascribed to genetic changes
as a result of in vitro culturing because similar data were obtained
when cell lines OE and RO were reinjected into mice. Also, the
experiments measuring the DNA index did not provide evidence
for such changes in the genetic material. The finding that tumours
with the original drug–response properties were obtained after
injection of cultured cells into mice was also published by Teicher
et al (1990). This phenomenon clearly indicates that results
obtained with cultured cells are not representative for the in vivo
situation. In vivo, apparently more important factors are involved,
for example vascularization. This difference between the in vitro
and in vivo results may be eliminated when the cells are grown in
a three-dimensional structure, e.g. as multicellular spheroids, as
shown for tumour cells by Kobayashi et al (1993), or as post-
confluent multilayered cultures, as shown by Pizao et al (1992).
In a comparative study with human ovarian carcinoma cell lines,
Kelland et al (1992) investigated the in vitro and in vivo anti-
tumour activity of cisplatin and three other platinum agents in eight
companion lines. In agreement with our results, these authors did
not find a correlation between in vitro SRB values and in vivo GDF
data. However, they reported a significant correlation – for cisplatin
only – between SRB results and tumour T/C values at 28 days, a
time point which seems rather arbitrarily chosen. In our study, the
lowest T/C ratio during the entire observation period was taken as
optimal T/C value. Because of the rapid growth rate of the HNSCC
xenografts, the 28-day time point could not be reached. It would be
interesting to investigate, for example, platinum content and plat-
inum–DNA adduct levels in the panel of ovarian carcinoma lines
described by Kelland et al (1992), which span a considerably wider
range of drug sensitivities than our HNSCC lines.
Significant correlations were found between the tumour
responses to cisplatin treatment in mice and the AUC of total plat-
inum levels present in the xenografts. Such a significant correla-
tion was also found for the corresponding cultured cells (Welters et
al, 1997a). Although the ranking of the sensitivities to cisplatin of
the HNSCC tumour lines and of the corresponding cell lines did
not correlate, the total platinum levels in both cases did correlate
with the sensitivity. Johnsson and Cavallin-Ståhl (1996) showed
that the platinum distribution within squamous cell carcinoma
tumours was fairly homogeneous, thus cisplatin was capable of
penetrating into the whole tumour. From this observation and our
results, it can be concluded that the tumour (cell) response is
reflected by the total platinum levels in the tumour cells.
In vitro, a relationship was established between cisplatin sensi-
tivity of the cultured cells and the level of the major intrastrand
cross-link, platinum–AG. This correlation was only found at 1 h
after the start of the treatment, suggesting that the level of DNA
damage immediately after cisplatin incubation is very important
for the efficacy of the treatment. However, in our panel of HNSCC
lines, no significant correlation was observed with the main
adduct, platinum–GG. Also, in the in vivo study, a significant
correlation was found between the sensitivity of the tumour and
the platinum–AG adducts. For this correlation, the AUC over the
3 h to 3 days interval after the second cisplatin treatment of the
mice was used, a time period during which the adduct levels
reached a maximum. After 3 days, these levels declined with time.
This finding was consistent with results described by Poirier and
co-workers (1992), who reported an increase in adduct levels in
various rat tissues between 4 h and 2 days after single and multiple
i.v. injection(s) of cisplatin followed by a decrease between days 2
and 7 and stable levels until 14 days. The AUC reflects the net
result of DNA adduct formation and DNA repair. The importance
of applying this AUC, derived from the platinum–DNA adduct
level vs time plot, has been emphasized by Schellens et al (1996),
who showed a correlation with the tumour response of this AUC in
WBC of patients. This parameter, calculated over a period of 15 h
after a 3-h cisplatin infusion, appeared to have a predictive value
for the tumour response of patients receiving daily treatments. The
fact that in the present study significant correlations were found
between the platinum–AG, but not the platinum–GG, adduct
levels and the HNSCC response suggests that platinum–AG plays
an important role in the anti-tumour effect in the HNSCC lines
studied. This finding is in agreement with the results of Fichtinger-
Schepman et al (1995b). These authors determined the quantities
of the various platinum–DNA adducts after treatment of Chinese
hamster ovary cells with equitoxic doses of cisplatin and carbo-
platin, and provided evidence that platinum–AG may be the cyto-
toxic lesion. The platinum–AG adduct has also been found to be
more mutagenic than platinum–GG (Burnouf et al, 1987; Yarema
et al, 1995) and it is more effectively repaired in a cisplatin-resis-
tant human testicular teratoma cell line (Hill et al, 1994). Los and
coworkers (1995) reported that the ratio of platinum–DNA
adducts to total platinum levels may be informative for the
response of the tumour to cisplatin therapy. They suggested that a
low ratio was indicative of high cellular detoxification due to
interaction with glutathione and metallothioneins. Calculation of
these ratios for our panel of tumour lines revealed that RO had
extremely high ratios at 3 h and 24 h after the cisplatin treatment
(data not shown; cf. Figure 2). This suggests that in this xenograft
a relatively large amount of the cisplatin is able to bind to cellular
DNA, resulting in a high level of platinum–DNA adducts, which
may explain the high cisplatin sensitivity of this tumour line. In the
other tumour lines, the ratio of platinum–GG adducts to the total
platinum content was about two- to tenfold lower, and in the case
of platinum–AG adducts 7- to 17-fold (cf. Figure 2). Thus, by
calculating the ratio of platinum–AG adduct to the platinum
content, the in vivo sensitivity to cisplatin may be predicted.
However, it is very important to sample at early time points after
the start of therapy. This predictive value should be tested in more
extensive studies. Because the pharmacokinetics of cisplatin have
been reported to be very similar in nude mice and humans (Kubota
et al, 1993), this ratio might also be very important for the predic-
tion of tumour response in patients. In the present study, the in
vitro sensitivity to cisplatin of HNSCC cells, however, was found
not to be related to this ratio of platinum–DNA adducts to plat-
inum content. This again is a discrepancy between the in vivo and
in vitro situation, which suggests that cell culture systems are not
reliable in predicting in vivo outcomes.
In conclusion, the different sensitivities to cisplatin in our panel of
HNSCC lines were significantly correlated with the total platinum
levels as well as with the platinum–AG adduct levels both in cultured
cells (in vitro) and in the xenografts (in vivo). These data support
previous evidence that platinum–AG may be the cytotoxic lesion.
However, results obtained for the cultured cells are not predictive for
the response to cisplatin of HNSCC tumours in nude mice.
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